About Tonghua Dongbao Pharmaceutical Company

The company was founded in 1985 and is a famous domestic pharmaceutical manufacturer integrating drug research and development, production and sales. In August 1994, the company was listed on the Shanghai Stock Exchange. Over the years, the company has set up a science and technology research and development team with the development concept of “adhering to independent innovation and creating a world brand”, and is committed to drug research and development in diabetes and other treatment fields. In 1998, China's first recombinant human insulin, “Gan Shulin”, was successfully developed, which not only filled the domestic gap, but also made China the third country in the world to produce recombinant human insulin after the US and Denmark. It is mainly engaged in pharmaceutical research and development, production and sales. The main business covers biological products, proprietary Chinese medicines, chemicals. The treatment fields are mainly diabetes, endocrinology, and cardiovascular medicine. Main products include human insulin raw materials, human insulin injections (registered trademark: Gan Shulin), glycine insulin raw materials, glycine insulin injections (registered trademark: Ping Shulin), Mendong insulin raw materials, Mendong insulin injections, Mendong insulin injections, Mendong insulin 30 injections, Mendong insulin 50 injections (registered trademark: Rui Shulin), Zhennao Ning capsules, diabetes-related medical devices, etc. Company honors: The company has a national enterprise technology center, a national GMP and EU GMP certified production workshop. It has been recognized by the state as a high-tech enterprise, a national technological innovation demonstration enterprise, and an ISO14001 environmental system certified enterprise.